Welcome to our dedicated page for Hemogenyx Pharma news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharma stock.
Hemogenyx Pharma PLC (HOPHF), associated with Hemogenyx Pharmaceuticals plc (LSE: HEMO), generates news primarily around its clinical development, financing, and strategic collaboration activities in biotechnology. The company describes itself as a clinical stage biopharmaceutical group developing new medicines and treatments for blood and autoimmune diseases, with a particular focus on its HG-CT-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML).
News updates frequently cover milestones in the Phase I clinical trial of HG-CT-1, including first-in-human dosing, safety evaluations, early signs of efficacy, and decisions by the independent Data Safety Monitoring Board on dose escalation. Additional coverage includes regulatory developments such as FDA interactions, Institutional Review Board approvals for pediatric enrollment, and broader trial design updates for both adult and pediatric patients.
Hemogenyx Pharmaceuticals also issues announcements on operational and strategic initiatives, such as its manufacturing partnership with Made Scientific to support HG-CT-1 production and its letter of intent with Cellin Technologies in Estonia to explore commercialization under the hospital exemption pathway. Capital markets news includes publication of a prospectus, share issuances arising from warrant exercises and restricted stock units, and updates on admission of new shares to the Official List and to trading on the London Stock Exchange.
Visitors to this news page can review a stream of company disclosures that document clinical progress, financing activities, manufacturing arrangements, and potential early revenue pathways. For investors and observers interested in CAR-T therapies, hematology-oncology, and early-stage biopharmaceutical development, Hemogenyx-related news provides insight into how the company is advancing its lead program and supporting infrastructure over time.
Hemogenyx Pharmaceuticals has announced that its Annual General Meeting (AGM) on June 25, 2021, will be a closed meeting due to COVID-19 restrictions in the UK. Only two specified Shareholders will attend to ensure quorum. Other Shareholders are encouraged to vote by proxy, appointing 'the Chair of the AGM.' While remote access will be provided for Shareholders to observe, they cannot vote electronically. The voting will occur via a poll to acknowledge proxy votes, with results published shortly after the AGM.
Summary not available.
Hemogenyx Pharmaceuticals has reported that as of May 28, 2021, its total issued share capital stands at 979,749,321 ordinary shares of 1 pence each, with no shares held in treasury. This figure represents the total number of voting rights in the company. Shareholders are advised to use this number as a denominator for any calculations regarding their investment obligations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Hemogenyx Pharmaceuticals has announced the admission of 433,333,333 new Ordinary Shares to the London Stock Exchange as part of the termination of a convertible loan note facility with Mint Capital Advisors. The company confirms that no convertible loan notes remain outstanding and will continue progressing its clinical trials. Notably, the shareholding of the founders has dropped below 20%, leading to the termination of their Relationship Agreement. Hemogenyx aims to enhance treatments for severe blood diseases.
Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF) reported that Financial Controller Andrew Wright acquired 1,088,120 ordinary shares at an average price of 1.8288 pence per share, totaling £19,899.54. This purchase increases Wright's holding to 2,715,111 shares, approximately 0.50% of the company's issued capital. The transaction, disclosed under Market Abuse Regulation, occurred on May 18, 2021, on the London Stock Exchange. The company emphasizes compliance with regulations regarding insider information.
Hemogenyx Pharmaceuticals has announced the termination of its agreement with Mint Capital regarding the £8.1 million convertible loan notes issued on February 3, 2021. The company will redeem £1.6 million of these notes, while Mint Capital will sell £6.5 million worth to investors, who will convert them into ordinary shares at 1.5 pence each. Following the conversion, no convertible loan notes will remain outstanding, allowing Hemogenyx to focus on advancing its clinical trials.
Hemogenyx Pharmaceuticals has announced the conversion of £500,000 in principal amount of Convertible Loan Notes, resulting in the issuance of 22,222,222 new ordinary shares at a conversion price of £0.0225 per share. This is set to take effect on May 17, 2021, with the total number of voting shares rising to 546,415,988 post-admission. The company has no immediate plans for further drawdowns from this Convertible Notes Facility. The new shares will share the same voting rights as existing shares.
Hemogenyx Pharmaceuticals has announced its final results for the year ended 31 December 2020, highlighting significant scientific advancements. Key achievements include the efficacy of HEMO-CAR-T cells against Acute Myeloid Leukemia, development of a new cell-based platform for treating emerging viral diseases, and collaborations with Eli Lilly and the University of Pennsylvania. Post-period, a Master Translational Agreement with the University was established, advancing HEMO-CAR-T towards clinical trials. The CEO emphasized the productivity and diversification of the company’s product pipeline.
Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF) has confirmed its total issued share capital as of April 30, 2021, consisting of 494,343,020 ordinary shares of 1 pence each, with no shares held in treasury. This total represents the number of voting rights available to shareholders and serves as a denominator for notifications regarding changes in shareholding under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Hemogenyx Pharmaceuticals announced the conversion of £900,000 in Convertible Loan Notes issued on February 3, 2021, into 29,850,746 new ordinary shares at a conversion price of £0.03015 each. Following the conversion, the company will have 524,193,766 ordinary shares in issue with voting rights. The admission of these new shares is expected on or around May 5, 2021. No immediate plans for further drawdowns from the facility have been indicated. This step is part of the company's ongoing efforts in developing treatments for blood and autoimmune diseases.